Audentes Therapeutics, Inc.
News
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
Globe Newswire SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...\n more…
Down -31.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Boundless Bio, Inc. (BOLD)
Zacks Investment Research A downtrend has been apparent in Boundless Bio, Inc. (BOLD) lately with too much selling pressure. The stock has declined 31.6% over the past four weeks. However, given the fact that it is now in...\n more…
Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO
FierceBiotech.com - Biotech Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO\njwaldron\nTue, 08/13/2024 - 04:28...\n more…
Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now?
Insider Monkey We recently compiled a list of the 10 Best New Penny Stocks To Buy Now. In this article, we are going to take a look at where Boundless Bio, Inc. (NASDAQ:BOLD) stands against the other new penny...\n more…
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nBOLD stock results show that Boundless Bio beat analyst estimates for earnings per share the second quarter of 2024.\nThe post BOLD Stock...\n more…
